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ABSTRACT
The p53 tumour suppressor is induced by various
stress stimuli and coordinates an adaptive gene ex-
pression programme leading to growth arrest or
cell death. Some stimuli, such as DNA damage,
lead to rapid and substantial multisite phosphory-
lation of p53, nucleated initially through phospho-
rylation of serine 15. Other stimuli, such as hyper-
proliferation, do not stimulate p53-phosphorylation,
raising questions regarding the physiological role for
phosphorylation. Here, we show that a basal level
of Ser15 phosphorylation occurs in both unstimu-
lated cells and cells stimulated pharmacologically
to induce p53. p53 in which Ser15 is substituted
by alanine (S15A) fails to mediate p53-dependent
transcription or growth arrest but can be rescued
by substitution with aspartate (S15D: a phospho-
mimic). Chromatin immunoprecipitation (ChIP) anal-
yses show that, while wt- and S15A-p53 are de-
tectable on the CDKN1A (p21) promoter (as a repre-
sentative p53-responsive promoter), S15A-p53 does
not stimulate histone acetylation (a measure of chro-
matin relaxation), nor is its recruitment stimulated, in
response to a DNA damage or pharmacological stim-
ulus. These data demonstrate that Ser15 phosphory-
lation is required for p53 function in the physiological
context of p53-responsive promoters and suggest a
key and possibly universal role even for low levels
of this modification in promoting p53-transcription
function.
INTRODUCTION
The p53 tumour suppressor is a short-lived transcription
factor that is stabilized and activated in response to a range
of cellular stresses including hyper-proliferation and DNA
damage (1,2). Induction of p53, regardless of the activat-
ing stimulus, is mediated mainly through uncoupling p53
from its key negative regulators, MDM2 andMDM4, lead-
ing to the accumulation of stable active p53 (3). Activated
p53 coordinates a flexible programme of gene expression
that is dependent upon the type and duration of the acti-
vating stimulus, the cell type and the growth status of the
cell (4,5). This response defines whether the biological out-
come of p53 induction will be cell-cycle arrest (transient or
permanent) or programmed cell death. However, themolec-
ular mechanisms by which the programme of gene expres-
sion varies under different conditions are only partly under-
stood.
At the molecular level, certain stimuli, such as geno-
toxic stress (DNAdamage-inducing agents) and glucose de-
privation, promote a series of reversible post-translational
modifications (PTMs) of p53 including multisite phospho-
rylation of the transactivation domain (N-terminus). In
addition to contributing towards the induction of p53,
these events are thought to regulate p53-mediated transcrip-
tion at individual promoters, possibly in a selective man-
ner (the ‘barcode’ hypothesis: (4–6)). Serine 15 is the pri-
mary target of the DNA damage response on the p53 pro-
tein and is phosphorylated by both the ATM and ATR
protein kinases (discussed in detail in (7,8)). Similarly,
activation of the AMPK protein kinase in response to
metabolic stress/glucose deprivation leads to phosphoryla-
tion of Ser15 (9).
Biochemically, Ser15 phosphorylation can stimulate as-
sociation of p53 with important histone/lysine acetyltrans-
ferases (HATs), such as p300 and CBP (10–12) Recruit-
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ment of these proteins promotes acetylation of multiple ly-
sine residues in the DNA binding and carboxy-terminal do-
mains of p53 and can thus contribute to the stabilization
of p53 by blocking ubiquitylation (13,14). However, it has
not been established to date whether, in the physiological
context of a p53-responsive promoter(s), Ser15 phosphory-
lation actually leads to corresponding local histone acety-
lation and relaxation of chromatin as the model predicts,
thereby permitting subsequent stimulation of transcription.
Ser15 phosphorylation also triggers a sequential series of
additional phosphorylation events in p53 (including phos-
phorylation of Ser9 -20, -46 and Thr18) that contribute fur-
ther to p53 induction and activation (14–18). These find-
ings suggest that Ser15 phosphorylation is therefore a ma-
jor focal point in the activation of p53. Biochemical ev-
idence suggests that these sequential modifications act in
the manner of a rheostat by incrementally increasing or
decreasing, respectively, association with partners, such as
p300 andMDM2, the principal ubiquitin E3 ligase that me-
diates ubiquitylation and proteasomal degradation of p53
(19–23). Curiously, however, while DNA damage promotes
phosphorylation of Ser15 (and indeed other sites in p53),
these modifications have not been reported to be stimu-
lated by other p53-activating events, such as the expression
of the physiological MDM2 inhibitor, ARF (which is in-
duced by hyper-proliferation) (24,25) or the pharmacolog-
ical MDM2 inhibitor, Nutlin-3a (24,26). Phosphorylation
of p53 has not, therefore, been deemed to be essential for
p53 function.
From an in vivo perspective, studies with knock-in mice
in which Ser18 (the murine orthologue of human Ser15) is
substituted by alanine have established that this phospho-
rylation site contributes to the protection against the late-
onset development of a variety of different tumours (27,28).
Analysis of cells derived from these mice (murine embry-
onic fibroblasts [MEFs] and thymocytes) suggest that Ser15
phosphorylation plays a role in selectively regulating p53-
dependent transcription in a cell type-dependent manner, at
least in murine cells, but themechanism(s) of this regulation
has not been established. In human cancer Ser15 phospho-
rylation occurs during the earliest stages of tumour develop-
ment (29) andmay, therefore, be an important element in ac-
tivating p53 tumour suppressor function. However, its con-
tribution to events that occur during cancer development,
and which may contribute to tumour suppression, is only
poorly understood.
In the present study, we have examined the role of Ser15
modification in a human cell background, in the physiolog-
ical context of events at p53-responsive genes with partic-
ular focus on the well-characterized CDKN1A (p21) p53-
responsive promoter. We show that Ser15 phosphorylation
occurs even in the absence of DNA damage stimuli and that
it is required for maximal promoter activity of various re-
sponsive promoters. Our data indicate that Ser15 phospho-
rylation is crucial, not only for DNA damage-induced acti-
vation of p53, but also, albeit at a lower level, for p53 activity
and biological function in response to the drug Nutlin-3a
which acts simply by blocking MDM2-mediated degrada-
tion of p53 and is representative of activators that do not
normally induce a significant increase in the stoichiometry
of Ser15 phosphorylation. Our data also show that Ser15
phosphorylation is required to permit local acetylation of
histones and relaxation of chromatin, thereby extending the
model whereby this modification promotes interaction with
HATs (above), and demonstrate that Ser15 phosphoryla-
tion is needed to recruit p53 to the promoter post-stimulus.
MATERIALS AND METHODS
Cell culture, mutagenesis and drug treatments
HCT116 (human colon carcinoma, wild-type p53), U2OS
(human osteosarcoma-derived, wild-type p53) and H1299
(non-small cell lung cancer derived, p53 negative) cell lines
were maintained in Dulbecco’s modified Eagle’s medium
with 10% fatal bovine serum (FBS). Ser15 substitution
mutants of human p53 were generated using the Strata-
gene QuikChange II system as directed by the manufac-
turer. Clonal (H1299-based) cell lines in which these pro-
teins were expressed in response to isopropyl beta-D-1-
thiogalactopyranoside (IPTG) inductionwere generated us-
ing the Stratagene LacswitchTM system. Clones were se-
lected and maintained in 400 g/ml hygromycin and 400
g/ml G418. Unless otherwise stated, clones were treated
with 100 M IPTG for 16 h prior to drug treatments to en-
sure expression of the relevant p53 protein. IPTGwasmain-
tained at 100 M during subsequent drug treatments.
Drug treatments of cells were carried out at final con-
centrations and incubation times as indicated in the figure
legends. Drugs were made up initially in dimethyl sulfoxide
(DMSO) or ethanol and used in independent experiments
as a check to ensure that the carrier itself did not stimu-
late any effects. As controls in several experiments carrier
(DMSO or ethanol) was present at a final concentration of
0.1% (v/v).
Western blotting and antibodies
Membranes were incubated with the monoclonal antibody
DO-1 (Moravian Biotechnology), CM1 (a kind gift from
Prof. Sir D. Lane) or PAb 1801 (sc-98; Santa Cruz) to
assess the presence and levels of p53. Other antibodies
used include phospho-p53 (Ser15) (#9284; Cell Signal-
ing Technology), p21 (sc-756; Santa Cruz Biotechnology),
H2AX phospho-S139 (ab11174; AbCam),MDM2 (SMP14
and 4B2; Moravian Biotechnology), anti-acetyl Histone
H3 (06–599; Upstate) and glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH) (G8795; Sigma). Western blotting
and visualization (chemiluminescence) were carried out us-
ing standard procedures.
Luciferase assays
H1299 cells were seeded at a density of 0.3 × 105 per well
onto a 24-well pate. The cells were transfected in triplicate,
using Fugene 6 transfection reagent (Roche), with fixed
amounts of plasmids encoding luciferase under control of
the p53-responsive p21-, BAX- or MDM2-promoters, or
the thymidine kinase (TK) promoter as control, together
with the SV-renilla plasmid for internal standardization.
Increasing amounts of plasmids expressing wild type or
mutant (S15A, S15D or L22Q/W23S) human p53, or an
empty expression vector (pcDNA3), were co-transfected as
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appropriate. Transfected cells were harvested 24 h post-
transfection in Passive Lysis Buffer (Promega) and analysed
in a luminometer using the Dual Luciferase Reporter Assay
Kit (Promega). Variations in transfection efficiencies were
corrected by determining the Renilla luciferase activity of
the sample.
Quantitative reverse transcriptase-polymerase chain reaction
(RT-PCR)
Total RNA was extracted using the RNeasy kit (Qiagen).
cDNA was made with a high capacity RNA-to-cDNA kit
(Applied Biosystems). Quantitative polymerase chain re-
action analysis (qPCR) was performed with QuantiTect
SYBRGreen PCR reagent (Qiagen) onApplied Biosciences
7500 Real Time PCR machine. GAPDH was used as an in-
ternal control. The primers used are as follows.
For chromatin immunoprecipitation (ChIP): ChIP analy-
sis was carried out at three points on the CDKN1A gene as
defined previously (30). These were at positions -2283, -20
and +8566. The primer used for these analyses were those
used by Donner et al. (2007) (30) and are given therein.
For mRNA quantitation the following primers were used:
CDKN1A (p21): forward - 5′-GGAGACTCTCAGGG
TCGAAA-3′
reverse - 5′-GGATTAGGGCTTCCTCTTGG-3′
PUMA: forward - 5′-GACCTCAACGCACAGTACGA
G-3′
reverse - 5′-AGGAGTCCCATGATGAGATTGT-3′
BAX: forward - 5′-CCCGAGAGGTCTTTTTCCGAG-
3′
reverse - 5′-CCAGCCCATGATGGTTCTGAT-3′
NOXA: forward - 5′-GGTCCCTAATCATGGACTCC
C-3′
reverse 5′-CTGTTTGCCAACTTGCTCCAC-3′
GAPDH: forward - 5′-GGCCATGGGAACTTCCCT
TA-3′
reverse - 5′-GCCATCCACAGTCTTCTGGGT-3′
Flow cytometry
Cells were collected and fixed in 80% ethanol for a mini-
mum of 2 h, followed by treatment with 0.2 mg/ml RNase
A in phosphate buffered saline. Propidium iodidewas added
subsequently to a final concentration of 25 g/ml. The cells
were analysed using a Becton Dickenson FACScan system.
Alamar blue assay
Cell viability was assessed using an Alamar Blue assay as
instructed by the manufacturer (Invitrogen).
ChIP
Following appropriate treatments, cells were cross-linked
using 1.5% formaldehyde. All subsequent procedures were
performed as described by Metivier et al. (31), with Dyn-
abeads (Invitrogen) used instead of protein A-sepharose
beads. The PCR primers used were those previously pub-
lished by Kaeser and Iggo (32).
Immunoprecipitation
H1299 cells (p53-null) were transiently transfected with
plasmids expressing wt-p53, p53-S15A or p53-S15D (en-
coded in the pCDNA.3 vector) with Lipofectamine 2000
(Invitrogen). Note that 24-h post-transfection the cells were
lysed in Igepal lysis buffer, and sonicated. The lysates were
then pre-cleared with 50 l Protein-G agarose beads (Santa
Cruz), before being incubated with the appropriate anti-
body overnight. Immune complexes were precipitated using
protein G-sepaharose 4B beads for 1 h at 4◦C with gentle
rocking. Immune complexes were washed and subsequently
analysed by western blotting.
RESULTS
Ser15 phosphorylation occurs following p53 induction inde-
pendently of DNA damage
We recently confirmed that major increases in the levels
of p53-Ser15 phosphorylation are induced only by cer-
tain stimuli (24). Thus, three DNA damage-inducing treat-
ments that activate p53 (etoposide [a clinically-relevant
anti-cancer drug], ultraviolet [UV] and ionising radiation
[IR]) induce Ser15 phosphorylation. Nutlin, a pharmaco-
logical inhibitor of the p53 negative regulator MDM2, acti-
vates p53 without inducing Ser15 phosphorylation (Figure
1A). Curiously, however, p53-dependent gene expression,
as measured by the induction of selected p53-downstream
genes including the cell-cycle inhibitor p21, appears to be
independent of increased phosphorylation of p53 ((24) and
Figure 1 panels A [protein expression] and B [mRNA lev-
els]), possibly suggesting that Ser15 phosphorylation is dis-
pensable for p53 activity (26). However, there is a low but
detectable level of phosphorylated Ser15 in extracts even
after induction of p53 by Nutlin-3a ((24); Figure 1A), sug-
gesting that a role for Ser15 phosphorylation cannot be dis-
counted.
Phosphorylation of Ser15 in response to DNA damage is
mediated through the ATM and ATR protein kinases (33–
35) and can be blocked using highly selective inhibitors of
these enzymes (KU55933 and VE821, respectively: Figure
1C). The combined ATR and ATM inhibitors also clearly
decreased Ser15 phosphorylation after Nutlin treatment
(Figure 1C), suggesting that basal, unstimulated levels of
ATM and/or ATR contribute to Ser15 phosphorylation in
the absence of DNA damage, at least in cultured cells. Ad-
ditionally, however, there appears to be a slight amount of
remaining phosphorylation in contrast to the situation with
etoposide. These data suggest that other protein kinases
known to phosphorylate Ser15 (8) may also contribute to
its modification in unstimulated and Nutlin-treated cells.
Consistent with the observation that both etoposide and
Nutlin treatments activate p53-mediated transcription, p53
recruitment to the distal site on the p21 (CDKN1A) pro-
moter (as measured by ChIP) is stimulated by each of
these drugs (Figure 1D). Notably, while treatment with
etoposide leads to a large increase in the presence of
Ser15-phosphorylated p53 at this promoter, there is also a
smaller but significant increase in the presence of Ser15-
phosphorylated p53 on the p21 promoter following treat-
ment with Nutlin-3a (Figure 1D). The increased signal with
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Figure 1. Induction of p53 and p53-phosphorylation by different stimuli. (A) U2OS cells, or HCT116 cells, were stimulated with increasing doses of
etoposide,Nutlin-3a,UVC radiation (UV) or ionising radiation (IR). The cells were harvested 6 h after treatment after which various proteins and phospho-
proteins were detected by western blotting as indicated. (B) HCT116 cells were treated with 50 M etoposide or 10 M Nutlin-3a and harvested after 6
h. The relative levels of expression of various p53-responsive genes were measured by quantitative RT-PCR as indicated. Error bars represent standard
deviation over the mean for three separate measurements. (C) HCT116 cells were pre-treated for 1 h with 10 M KU55933, 10 M VE821 or with both
compounds. The cells were then treated, in the presence of these inhibitors, for a further 6 h with 50 M etoposide or 10 MNutlin-3a, as in panel A, and
subsequently harvested. Various proteins and phospho-proteins were detected by western blotting as indicated. (DMSO or ethanol were used as carrier
[drug solvent] in independent experiments and were present at a final concentration of 0.1% [v/v]). (D) HCT116 cells were treated for 3 h or 6 h with 50
M etoposide or 10 MNutlin-3a. ChIP analysis was carried out on the p21 promoter (distal site) using the various indicated antibodies.
the anti-acetylated histone H3 antibody indicates the oc-
currence of chromatin relaxation and is consistent with in-
creased transcription. These data suggest a potential role
for low levels of modification at this site.
Serine 15 is important for p53-mediated gene expression
To determine whether Ser15 phosphorylation is important
for human p53 function, luciferase assays were carried out
in which wild-type p53 and phosphorylation site mutants
were compared for their abilities to mediate p53-dependent
transactivation. The data (Figure 2) confirmed that wild-
type p53 transactivates expression from the p21-, BAX- and
MDM2-promoters in a dose-dependent manner (panels A–
C, respectively). As control, increasing levels of p53 showed
no effect on the non-p53-responsive TK-promoter (data not
shown). A mutant p53 protein in which the Ser15 phos-
phorylation site was substituted by alanine, and which can-
not therefore be phosphorylated, showed a significant re-
duction in its ability to promote expression from the BAX-
and MDM2 promoters, consistent with a requirement for
Ser15 phosphorylation for full transcriptional activity. In-
terestingly, the S15A mutant was unable to induce expres-
sion from the p21-promoter at any of the levels tested. In
all cases a S15D substitution mutant was equally effective
at stimulating gene expression as compared with wild-type
p53. Given that aspartate or glutamate substitutions can of-
ten mimic phosphorylated residues, these data are consis-
tent with the idea that Ser15 phosphorylation is required
for effective p53-dependent transactivation. The inclusion
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Figure 2. Serine 15 in human p53 is required for efficient p53-mediated transactivation of responsive promoters. Luciferase assays were carried out as
described in theMaterials andMethods section. In brief, H1299 cells were transfectedwith plasmids encoding luciferase under control of the p53-responsive
p21-, BAX- or MDM2-promoters, together with the SV-renilla plasmid for internal standardization. Increasing amounts of plasmids expressing wild type
or mutant (S15A, S15D, L22Q/W23S, S392A, S392D) human p53, or an empty expression vector (pcDNA3), were co-transfected as appropriate. The
cells were harvested 24 h after transfection. The levels of the expressed p53 proteins were determined for each transfection by western blotting using the
antibody DO-1. (In the case of the L22Q/W23S mutant, which is not recognized by DO-1, CM-1 was used for detection.) Since these were consistent from
experiment to experiment, typical western blots are shown in panels D and H.
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of the transcriptionally inactive L22Q/W23S double mu-
tant (36) as a negative control underpinned the requirement
for transactivation domain 1 of p53 (TAD1, which contains
the Ser15 phosphorylation site) in expression from these
promoters. These data strongly suggest that Ser15 phospho-
rylation is required for p53-dependent gene expression and,
given the case of the p21-promoter, suggest that this residue
may play a selective and promoter context-dependent role
in transactivation.
In contrast to these data, substitution of another ma-
jor p53 phosphorylation site, Ser392, had no detectable ef-
fect on p53 activity under the conditions employed in this
study (panels E–G). This observation underpins the speci-
ficity and contribution of the Ser15 phosphorylation site. In
all cases the levels of expression of the wild-type andmutant
p53 proteins were checked to ensure that lack of transacti-
vation in the reporter plasmids could not be attributed to
differences in the levels of expression (panels D and H).
Inducible expression of wild-type and phosphorylation site
mutant p53 proteins at near-physiological levels highlights a
crucial role for Ser15 phosphorylation in mediating growth
arrest
While the data from the luciferase assays give a strong indi-
cation that Ser15 phosphorylation has profound effects on
downstream p53 transcription, they rely on ectopic expres-
sion of p53 and the use of reporter plasmids as targets. It is,
therefore, important to explore the influence of Ser15 phos-
phorylation on endogenous p53-responsive genes.However,
given that the levels of endogenous p53 proteins play a criti-
cal role in p53-mediated gene expression and biological out-
come, it is necessary to be able to express the phosphoryla-
tion substitution mutants at physiological levels in all cells
of a given population. To address this problem, clones of
H1299 cells ectopically expressing wild-type or mutant p53
using the IPTG-inducible LacSwitch II system were gener-
ated and screened, as described in the Materials and Meth-
ods section (Figure 3A). (We have used this system previ-
ously to investigate the contribution of p53 phosphoryla-
tion to regulation of BCL-3 expression (37). H1299 cells are
ideal for this purpose because they lack endogenous p53 ex-
pression.) The advantage of this system is that it allows low
but controllable levels of expression that can be adjusted to
match the levels of expression of endogenous p53 in other
established cultured cell lines.
Three clones expressing wt human p53, three expressing
the S15A mutant and three expressing the S15D mutant
were adopted for further analysis. For presentation pur-
poses, the data from only one of each type (WT5, A9 and
D1) are shown in the figures, unless stated otherwise, but
are representative of similar observations made using the
other clones. All clones showed p53 expression that is in-
ducible by IPTG (Figure 3B) and detectable by two inde-
pendent p53-specific monoclonal antibodies with different
epitopes (DO1 and PAb1801). Notably, Ser15 phosphory-
lation was detectable in the absence of any stress stimulus
and was observed only with wt p53 but not with the S15A
or S15D proteins. Consistent with the luciferase data, both
the wt and S15D proteins stimulated the levels of endoge-
nous p21. However, p21 was barely detectable in the S15A
clone.
To determine whether the expression of the p53 proteins
had any biological effects on cell status, growth curves were
carried out. These data (Figure 3C) show that IPTG stim-
ulation (and consequent p53 expression) led to a reduced
growth rate in the case of the wt p53- and S15D-expressing
clones but not the S15A or, importantly, the parental H1299
cells, both of which were unaffected by IPTG treatment.
Consistent with these findings, cell-cycle distribution analy-
ses, 24 and 48 h after IPTG treatment (Figure 3D), showed
an increase in the proportion of G1 cells and corresponding
decrease in the S phase population in the wt p53-expressing
clones but no change in the cells expressing the S15A mu-
tant. The cells expressing the S15D mutant, which, in the
absence if IPTG, had an increased G1 population as com-
pared with the wt p53-expressing cells, showed a remark-
able increase the G1 and G2/M populations that was ac-
companied by a significant reduction in S phase cells. No-
tably, there was little increase in the sub-G1 cell popula-
tion suggesting that, in the H1299 cell system, the induction
of p53 led principally to growth arrest and not cell death.
Alamar Blue analysis confirmed that, following IPTG treat-
ment, the wt p53 and, particularly, the S15Dmutant, signif-
icantly down-regulated cell proliferation, whereas the S15A
mutant showed nomeasurable effect. These clonal lines can,
therefore, mimic the induction of endogenous p53 and un-
derscore the importance of Ser15 phosphorylation in medi-
ating growth arrest.
S15A mutant proteins fail to support p53-dependent tran-
scription in response to Etoposide or Nutlin
To determine whether substitution of Ser15 phosphoryla-
tion had any influence on the ability of p53 to stimulate
endogenous gene expression, clonal lines were treated with
IPTG to induce expression of wt, S15A or S15D p53 and
were subsequently further treated with etoposide for up to
6 h. The data (Figure 4A) indicate that the short etopo-
side treatment did not increase the p53 levels in any of the
clones over and above those obtained with the IPTG. The
wild type clone showed a dose-dependent stimulation of
p21 protein levels. In the S15D clone, p21 levels are high,
even in the absence of etoposide, and are not significantly
increased by etoposide treatment, consistent with the idea
aspartate is mimicking constitutive phosphorylation at this
site. In contrast, p21 expression was barely detectable in the
S15A clone. Interestingly, however, prolonged exposure of
a p21 western blot revealed that there was still a degree of
p21 inducibility following etoposide treatment, albeit start-
ing from a very low basal level (panel A inset). Notably,
the levels of p53 expression, and the downstream response,
achieved using the LacSwitchII system were broadly simi-
lar to the endogenous p53 response seen in HCT116 cells.
These data underpin the value of using this inducible system
to study the human p53 phosphorylation site mutants.
To confirm that the lack of induction of p21 protein in
the S15A mutant reflected a reduced stimulation of mRNA
levels, comparative analysis of selected p53-dependent gene
expression in the wt and S15A clones was carried out us-
ing quantitative RT-PCR. The data confirmed that p21 ex-
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Figure 3. Clones of H1299 cells expressing wild-type or phosphorylation site-mutant p53 proteins. (A) Representation of p53 cDNA under inducible
control from the RSV promoter in the LacSwitch II system. (B) Western blot analysis of typical p53-expressing clones following induction by increasing
concentrations of the inducer, IPTG. (C) Growth curves of typical p53-expressing clones in the absence and presence of increasing doses of the inducer,
IPTG. The cells were seeded at 5 × 104 cells per dish and treated with 0, 0.1 or 1 mM IPTG. The cells were harvested and counted at 2-day intervals for up
to 6 days. (D) Cell-cycle distribution of clones in the absence and presence for 24 h (upper panel) and 48 h (lower panel) of 1 mM IPTG. (E) Alamar Blue
growth curves of typical clones in the absence and presence of 1 mM IPTG.
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Figure 4. Effect of etoposide on p53 downstream gene expression in H1299 cell clones expressing wild-type or phosphorylation site mutants of p53. (A)
Clones of H1299 cells were pre-treated with 100 M IPTG to permit expression of the wild type, S15A or S15D p53 proteins. The cells were then treated
for up to 6 h with 50 M etoposide and subsequently harvested. Various proteins and phospho-proteins were detected by western blotting as indicated.
HCT116 cells were treated in a similar manner to compare the p53 levels and responses with an endogenous p53 response. (B) The levels of expression
of various p53-responsive genes before and after the etoposide treatment were measured by quantitative RT-PCR in the wt and S15A clones. The levels
achieved following drug stimulation are expressed relative to the uninduced levels in the same clonal line.
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pression failed to show any response to induction of the
S15A mutant (Figure 4B). Similarly, the small induction of
PUMA seen in this cell background in response to etopo-
side was absent in the S15A-expressing cells. Notably, BAX
and NOXA were not significantly induced in this context.
Similar experiments were conducted in which p53 was in-
duced using Nutlin-3a (Figure 5), which works by inhibit-
ing MDM2 and does not stimulate a major increase in p53
phosphorylation (38). Again, while p21 and MDM2 were
induced in the wt p53 and S15D clones, the levels of these
proteins were very low in the S15A clone (Figure 5A). These
data are consistent with a requirement for Ser15 phospho-
rylation for p53 activity, even when the inducing agent is
not one that normally stimulates high levels of phospho-
rylation. Comparative analysis of selected p53-dependent
gene expression in the wt and S15A clones by quantitative
RT-PCR showed that, in response toNutlin, all of the genes
(p21, BAX, NOXA and PUMA) were induced by wt p53
but, strikingly, were unaffected in the cells expressing the
S15A mutant p53 (Figure 5B). The significant differences
in the magnitude of induction of these genes in response
to maximal levels of Nutlin as compared with maximal lev-
els of etoposide (Figure 4) may simply reflect characteristics
of a particular dose of inducer. Alternatively, it is possible
that these activators may affect p53-mediated transcription
through their established influence on other cross-talking
pathways (see Discussion).
Ser15 is required for efficient recruitment of p53 to chromatin
It is well established that Ser15 phosphorylation stimu-
lates the interaction of p53 with key transcriptional proteins
(8,39) but how modification of this residue regulates events
in the physiological context of chromatin has not been
established. To explore the role of Ser15 modification in
switching on p53 function, comparative ChIP experiments
were carried out using the wt p53- and S15A-expressing
clones and focusing on the p21 promoter as a model pro-
moter. Examination of recruitment of p53 to three sites was
carried out: the distal p53-responsive element (at −2283 bp
from the transcriptional start site: Distal), and, as controls,
at the core promoter (−20 bp: C) and the 3′ end of the gene
(+8566: F) (Figure 6A).
The data show that, in response to etoposide treatment,
p53 was recruited to the distal element of the p21 promoter
but was not detectable at either the core promoter or the 3′
end of the gene (Figure 6B). In the unstimulated cells, the
level of occupancy of wt p53 and the S15Amutant were sim-
ilar; (p53 has previously been shown to occupy this site prior
to any activating stimulus (40)). Interestingly, however, fol-
lowing stimulation with etoposide, while the recruitment of
the wild-type proteins was stimulated by several fold, re-
cruitment of S15A-p53 was significantly weaker, suggesting
that Ser15 phosphorylation is required for association of
p53 with this promoter post-induction. The control anal-
yses confirmed that p53 was not recruited to the core pro-
moter or coding region of the gene.
When different p53 antibodies recognising different p53
epitopes were used in the ChIP experiment to immuno-
precipitate the p53, similar data were obtained (panel C),
underpinning that the result was not antibody-specific nor
was it the consequence of masking and/or modification
of an epitope. Importantly, the acetylation of histone H3,
a marker for histone acetylase (e.g. p300/CBP) recruit-
ment, chromatin relaxation and transcription activation,
was stimulated within the vicinity of the distal responsive
element only in the case of the wt p53 (panel E). These data
suggest, mechanistically, that the lack of Ser15 phospho-
rylation led to a failure to engage this important step in
transcriptional activation. The lack of histone acetylation
observed with the S15A mutant is consistent with the bio-
chemical model that Ser15 phosphorylation plays a key role
in mediating association with HATs (10–12,19–23). When
Nutlin was used as the stimulus in place of etoposide, very
similar results were obtained (Figure 6D and F).
The recruitment of the S15Dmutant to the p21 promoter
was also examined (Figure 6G). The data indicate a slightly
stronger occupancy than wild-type p53, consistent with a
requirement for phosphorylation of Ser15. The data also
show that, as with wild-type p53, the recruitment is further
increased following etoposide or nutlin treatment. These
findings suggest that additional factors (such as increases in
p53 levels or subsequent additional PTMs) are likely to con-
tribute to the stimulus-dependent increase in recruitment.
Taken together, these observations demonstrate that Ser15
phosphorylation is required for p53-mediated p21 expres-
sion even by stimuli that do not give rise to major increases
in phosphorylation.
Serine 15 substitution does not alter the conformational sta-
tus of p53
The site-specific binding of p53 to DNA relies upon the
core (DNA binding) domain of p53 adopting an appropri-
ate conformation; (the so-called ‘wild type’ conformation).
p53 conformational status is flexible in cells, is temperature-
dependent and can be influenced by several factors (41).
Moreover, many mutations that occur within the core do-
main in human cancers shift the equilibrium away from a
DNA binding conformation to the so-called ‘mutant’ con-
formation. Given the importance of conformational status
for DNA binding, the conformations of wild-type p53, to-
gether with the S15A and S15D mutant proteins was as-
sessed using the anti-p53 conformation-specific antibodies
PAb1620 (which recognizes p53 only in its ‘wild type’ [site-
specific DNA binding] conformation) and PAb240 (which
recognizes an epitope in p53 that is masked when the pro-
tein adopts the wild type conformation). Analysis of cell
extracts (Figure 7) revealed that PAb1620 was able to im-
munoprecipitate the S15A and S15D mutant p53 proteins
as effectively as wild-type p53. PAb240 recognizes only a
small proportion of each of the three proteins. An R175H
mutant p53 protein was immunoprecipitated only by the
PAb240 antibody, thereby confirming the specificity of these
conformation-specific antibodies. These data indicate that
Ser15 modification is highly unlikely to affect association
of p53 with chromatin by regulating changes in the confor-
mation of the p53 core domain.
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Figure 5. Effect of Nutlin-3a on p53 downstream gene expression in H1299 cell clones expressing wild-type or phosphorylation site mutants of p53. Clones
of H1299 cells were pre-treated with 100 M IPTG to permit expression of the wild type, S15A or S15D p53 proteins. The cells were then treated for up
to 8 h with 10 MNutlin-3a and subsequently harvested. Various proteins and phospho-proteins were detected by western blotting as indicated. HCT116
cells were treated in a similar manner to compare the p53 levels and responses with an endogenous p53 response. The ‘+ve’ lane is an additional control
in which the HCT116 cells were treated with 50 M etoposide (as in Figure 5). (B) The levels of expression of various p53-responsive genes before and 6 h
after the Nutlin treatment were measured by quantitative RT-PCR in the wt and S15A clones. The levels achieved following drug stimulation are expressed
relative to the uninduced levels in the same clonal line.
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Figure 6. Serine 15 substitution inhibits association of p53 with the p21 promoter. (A) Schematic representing the p21 gene indicating the positions of the
probes and primers used in this study. (B) The levels of p53 recruited to the distal p53-responsive element (Distal), the core promoter (C) and the 3′ end (F)
of the p21 gene in H1299 cells expressingWT- and S15A-p53, before and 6 h after treatment with etoposide, were measured by quantitative ChIP using the
anti-p53 antibody DO1. (Cells had been pre-treated with 100 M IPTG prior to etoposide treatment to permit expression of the p53 proteins.) Data points
were obtained in triplicate and mean values with associated errors are shown. As control, the DO-1 antibody was substituted with a non-specific IgG. (C)
Comparative ChIP analysis of the Distal response element was carried out as in panel B using three independent anti-p53 antibodies (DO-1, PAb1801 and
CM-1). With each antibody the increased occupancy following stimulation is presented relative to the untreated samples. (D) Comparative ChIP analysis
of the Distal response element was carried out as in panel B except that Nutlin was used as the stimulus in place of etoposide. (E and F) The levels of
acetylated histone H3 were determined by ChIP using an anti-acetylated histone H3 antibody (Ac-H3). The cells were stimulated with etoposide (E) or
Nutlin (F). (G) The levels of p53 (left-hand panel) and acetylated H3 (right-hand panel) at the Distal p53-RE of the p21 gene in H1299 cells expressing
WT- or S15D-p53 before and 6 h after treatment with etoposide, were measured by quantitative ChIP as above.
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Figure 7. Serine 15 substitution does not alter the conformational status
of p53. Plasmids expressing WT p53, p53-S15A, p53-S15D or the con-
formational mutant p53-R175H (as control) were transfected into H1299
cells. 8 h after transfection, lysates were prepared and the p53 proteins
immunoprecipitated using the conformation-specific antibodies, PAb1620
(WT conformation-specific) or PAb240 (mutant conformation-specific).
The immunoprecipitated proteins were detected by western blotting using
the DO-1 antibody.
DISCUSSION
The significance of Ser15 phosphorylation in p53
Ser15 is a major target for phosphorylation in the p53 pro-
tein. In the present study, we show that the contribution of
this pivotal modification is much wider than had previously
been anticipated. The significance of our findings are es-
sentially 3-fold. (i) We show for the first time that a model
for the regulatory role of this phosphorylation site, previ-
ously developed on the basis of biochemical analyses, op-
erates within the physiological context of p53 transactiva-
tion function at p53-responsive promoters, i.e. at the major
sites of p53 biological activity. (ii) We also find that Ser15
phosphorylation is important not only for the recruitment
of histone acetyl-transferases to promoters, leading to chro-
matin relaxation, but also plays an unexpected role in the re-
cruitment of p53 itself to chromatin. (iii) Crucially, our data
overturn the assumption that the regulatory contribution
of Ser15 phosphorylation is restricted to only certain (i.e.
DNA damage and glucose depletion) of the many stimuli
that activate p53, and reveal that this important PTM plays
a fundamental role in regulating p53 function irrespective
of the intitiating stimulus.
Ser15 phosphorylation is required for p53 function in the
physiological context of p53-responsive promoters
Ser15 phosphorylation is robustly induced by some stress
stimuli (such asDNAdamage) but not by others (7,8). Here,
we show that both basal (uninduced) p53, and indeed p53
that is induced simply through inhibition of MDM2, show
detectable levels of Ser15 phosphorylation, at least in cul-
tured cells. To address a possible role for thismodification in
a physiological context we generated cell lines that express
levels of wild type or phosphorylation site-substitution p53
proteins, in response to IPTG treatment, that match the lev-
els of p53 seen in commonly used p53-responsive human
cell lines. (We have used similar lines previously to study the
regulation of cyclin D1 expression by p53 (37).) The data
generated from the analysis of these lines have established
several important principles: (i) Ser15 phosphorylation is
required for full p53 transcriptional activity and for its bi-
ological response, at least in terms of cell-cycle arrest. The
use of a phospho-mimic (the S15D substitution mutant),
which rescues the transcriptional activity and cell-cycle ar-
rest functions absent from the S15A mutant, strongly sug-
gests that the biological requirement for Ser15 lies its ca-
pacity to act as a major phosphorylation site. (ii) A model
based on these findings, describing the role of Ser15 phos-
phorylation within the physiological context of chromatin,
is entirely consistent with previously published biochemical
data showing that the modification promotes tight associ-
ation with histone acetyl-transferases, such as p300/CBP
(10–12,19–23) (Figure 8 and see below). (iii) While some
stress stimuli, such asDNAdamage, promote significant in-
creases in the stoichiometry of Ser15 phosphorylation, there
does indeed appear to be a universal requirement for phos-
phorylation of this residue in maintaining full p53 tran-
scriptional and biological activity, even when p53 is induced
by stimuli that do not normally stimulate its phosphoryla-
tion. This would imply that phosphorylation of Ser15 me-
diates possibly two separable functions of p53: one of these
underpins basic transactivation function (part of which is
HAT recruitment (10–12)) and is likely to be common to
all modes of activating p53. At the same time, however,
the DNA damage and glucose deprivation pathways stim-
ulate large increases in the level of Ser15 phosphorylation:
such increases may reflect true increases in stoichiometry of
phosphorylation (e.g. they could be a measure of howmany
subunits within the p53 tetramer are phosphorylated). Al-
ternatively, given that the level of phosphorylation mea-
sured in cell extracts reflects an ‘average’ of all of the p53
molecules in the cell, the increased phosphorylation could
be a representation of the length of time p53 molecules
exist in the phosphorylated state. While the present study
does not experimentally address any possible second role
for Ser15 phosphorylation, the striking difference in the lev-
els and/or duration of Ser15 phosphorylation induced by
etoposide as compared with Nutlin suggests that there is a
specific need for these higher levels, such as mediating in full
the events set in motion by the genotoxic stimulus. For ex-
ample, it is well established that different stress stimuli that
impact p53 promote the assembly of transcriptional com-
plexes that differ in their constituent components (40). It is,
therefore, possible that increased or prolonged phosphory-
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Figure 8. Schematic describing a model for the role of Ser15 phosphoryla-
tion in p53-mediated transactivation. (1) p53 undergoes phosphorylation
on Ser15. (2) This permits recruitment of histone acetyl-transferases (e.g.
p300) (2) leading to acetylation of histones in the neighbouring vicinity (3)
and subsequent relaxation of the chromatin (4). The inability to phospho-
rylate p53 at residue 15 (e.g. in the S15Amutant) impedesHAT recruitment
and subsequent histone acetylation.
lation of Ser15 may be necessary to permit the required in-
teractions promoted by some stress stimuli but not by oth-
ers.Moreover, in addition to acetylating various C-terminal
lysine residues in p53, and in modifying neighbouring his-
tone proteins, CBP/p300-mediated acetylation of K164 in
the DNA binding domain of p53 is important for the ex-
pression of genes involved in growth arrest (42). Increased
phosphorylation could have an impact on the outcome of
recruiting CBP/p300, such as the relative extent to which
these proteins acetylate specific sites within p53 or indeed
the neighbouring histones. These are issues which future
analysis of the role of Ser15 phosphorylation should ad-
dress.
Curiously, we have also found consistently in this study
that the maximum level of p53-dependent gene expression
achieved following Nutlin treatment is significantly greater
in magnitude than that seen maximally with etoposide. The
most plausible explanation for this observation lies in the
ability of these p53 activators to affect other pathways. For
example, the NFB pathway, which is also activated by
DNA damage, generally acts through several mechanisms
to down-regulate p53 transcriptional activity. In response to
DNA-damaging agents, such as etoposide, IKK phospho-
rylates CBP on two serines which prevents CBP from inter-
acting with p53 (43). CBP and p300, which are thought to
be limiting components for transcriptional activation, are
therefore likely to be rate-limiting for p53-mediated tran-
scription following DNA damage, especially in HCT116
cells which are hemizygous for mutant p300 (44). Nutlin,
on the other hand, downregulates TNF--induced activa-
tion of NFB, at least in some cells (45), and may therefore
prevent sequestration of CBP or other factors from p53.
A model for the role of Ser15 phosphorylation in regulating
p53 transcription function
From a mechanistic perspective, the data define a model for
the requirement for Ser15 phosphorylation in the physio-
logical context of mediating changes in chromatin that pro-
mote transactivation. Thismodel states that the recruitment
of p53 to promoters under non-stimulation conditions (at
least the CDKN1A [p21] promoter, which is the focus of
the present study) occurs essentially independently of Ser15
phosphorylation. In support of this conclusion, we find that
(i) the ChIP data show roughly equal levels of wt or S15A
p53 on the p21 promoter prior to a DNA damage or phar-
macological stimulus (Figure 6 panels B andD); and (ii) the
so-called ‘wild type’ (site-specific DNA binding) conforma-
tion of p53 is unaltered by substitution of Ser15 (Figure 7).
Upon stimulation, wild-type p53 mediates transactivation
of p21 (Figures 4 and 5): this requires recruitment and/or
activation of HAT function as shown by the increased his-
tone acetylation in the immediate vicinity of the distal p53-
binding site (ChIP data: Figure 6 panels E–G). Notably, the
S15A mutant p53, while located at the p53 binding site, is
unable to mediate histone acetlyation and is unable to pro-
mote transactivation, even in unstimulated conditions (Fig-
ures 4 and 5). These observations are entirely consistent
with the published biochemical data (10–12,19–23) show-
ing that Ser15 phosphorylation is required for optimal in-
teraction with the HATs CBP and p300 (the major HAT
involved in p53-dependent relaxation of chromatin at the
p21 promoter (46)).
It is not clear why the increased recruitment to the p21
promoter observed with the wild-type p53 protein is absent
with the S15Amutant. One possibility is that the rate of ac-
cumulation of S15A p53 on the promoter is much slower
that that of the wild type protein. The on-rates for p53 site-
specific DNA binding have been reported to be exceedingly
fast (47,48). This, taken together with the known ‘wild type’
conformation of the S15A p53 (Figure 7), suggests that di-
rect DNA binding is highly unlikely to be affected by the
S15A substitution. Given, however, that p53 binds signifi-
cantly more tightly to chromatin than to naked DNA (46),
the phosphorylation may speed up recruitment by helping
anchor p53 to nearby nucleosomes and/or components of
the transcription machinery. It is also possible that the as-
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sembly of complexes with transcriptional proteins may re-
duce the off rate for p53 binding: in support of such an idea
it was previously established that the binding of antibod-
ies to epitopes in the N-terminus of p53 can significantly
reduce p53 dissociation from the DNA (48). Alternatively,
the increased wt- but not S15A-p53 association with the
promoter could be explained if the promoter exists in two
states within a cell population, one of which is open and per-
missive for binding both p53 species (Ser15-phosphorylated
and unphosphorylated), and a second fraction that requires
remodelling before p53 can bind effectively. Wt p53 was re-
cently shown to have properties of a pioneer transcription
factor and is capable of binding to responsive elements on
the surface of nucleosomes (49). Thus, if Ser15 were critical
for this pioneering activity, then only wt p53 would show
increased binding and transactivation after treatment.
Potential relevance of Ser15 phosphorylation to wider p53-
mediated events
In addition to its classical role in responding to cellular
stresses, such as DNA damage, p53 is now known to make
important contributions to a range of homeostatic pro-
cesses including maternal reproduction, metabolism and,
importantly, the biology of stem cells where it can impact on
processes, such as self-renewal, differentiation and plastic-
ity (50). A key feature of the ability of p53 to regulate these
aspects of stem cell function is its ability to down-regulate
the expression of critical genes, such as Nanog and Oct4,
which drive embryonic stem cell self-renewal and dediffer-
entiation. The crucial role of stem cells, both in embryogen-
esis and in adult tissue and organ renewal, necessitates high
fidelity in maintaining genomic stability and in responding
to the occurrence of genetic lesions. It will be interesting,
therefore, to determinewhether themodel defining the func-
tion of Ser15 phosphorylation (Figure 8) also impacts on
the regulation of genes involved in these other processes by
governing the recruitment of p53 and defining its interac-
tion with relevant partner proteins. This would be of partic-
ular interest given the involvement of other DNA damage-
inducible phosphorylation sites in p53 in stem cell biology.
For example, Ser315 phosphorylation plays a role in con-
trollingNanog expression (51).Moreover, mutantmice har-
bouring aspartate substitutions in two key DNA damage-
inducible phosphorylation sites, Thr21 and Ser23 (equiva-
lent to humanThr18 and Ser20), show depletion ofmultiple
stem cell populations, mainly through p53-mediated expres-
sion of PUMA (52).
Central role of ser15 phosphorylation
Finally, p53 has been estimated to undergo about 60 differ-
ent PTMs (53). More recently, however, an additional 150
PTMs, not previously reported, were identified on p53 in a
single cell type by mass spectrometry (54). In spite of this
extensive list of modifications, and the corresponding eye-
watering number of permutations that may exist, Ser15, one
of the first discovered sites of modification in p53, clearly
plays a fundamentally important role in p53 function and
biology––more so given that it is a primary target of cer-
tain stress stimuli (such as DNA damage) and can trigger
many subsequent functionally important PTMs of the p53
protein ((55) and references therein).
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